Item request has been placed!

Item request cannot be made.

Processing Request

نتائج البحث

Display Settings

النتائج لكل صفحة: 10

Sort By: Relevance

Filter

فلترة النتائج

إعادة تعيين خيارات الفبترة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Fabrication of PEGylated Chitosan Nanoparticles Containing Tenofovir Alafenamide: Synthesis and Characterization.

Authors : Zaman, Muhammad¹ (AUTHOR) ; Butt, Muhammad Hammad² (AUTHOR) ; Siddique, Waqar^3,4 (AUTHOR)

Source: Molecules. Dec2022, Vol. 27 Issue 23, p8401. 19p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Evaluation Effect of Tenofovir Alafenamide (TAF) in Long-Term Therapy for Chronic Hepatitis B: A Systematic Review.

Authors : Saputra, Rada Citra¹; Hidayat, Nur²

Source: Indonesian Journal of Gastroenterology, Hepatology & Digestive Endoscopy. Dec2022, Vol. 23 Issue 3, p216-225. 10p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.

Authors : Jung, Chan‐Young¹ (AUTHOR); Kim, Hyung Woo¹ (AUTHOR); Lee, Jung Il² (AUTHOR)

Source: Liver International. Nov2022, Vol. 42 Issue 11, p2408-2417. 10p. 1 Diagram, 3 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.

Authors : Lee, I-Cheng^1,2 (AUTHOR) ; Lan, Keng-Hsin^1,3 (AUTHOR); Su, Chien-Wei^1,2 (AUTHOR)

Source: International Journal of Molecular Sciences. Oct2022, Vol. 23 Issue 19, p11335. 14p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study.

Authors : Ogawa, Eiichi¹ (AUTHOR) ; Nakamuta, Makoto² (AUTHOR); Koyanagi, Toshimasa³ (AUTHOR)

Source: Alimentary Pharmacology & Therapeutics. Aug2022, Vol. 56 Issue 4, p713-722. 10p. 3 Charts, 3 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B.

Authors : Lim, Jihye¹ (AUTHOR); Choi, Won‐Mook¹ (AUTHOR); Shim, Ju Hyun¹ (AUTHOR)

Source: Liver International. Jul2022, Vol. 42 Issue 7, p1517-1527. 11p. 2 Charts, 4 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

HERACLIS‐TAF: a multi‐centre prospective cohort study on 2‐year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.

Authors : Papatheodoridis, George V.¹ (AUTHOR) ; Mimidis, Kostas² (AUTHOR); Manolakopoulos, Spilios^1,3 (AUTHOR)

Source: Alimentary Pharmacology & Therapeutics. Aug2022, Vol. 56 Issue 4, p702-712. 11p. 3 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.

Authors : Kayes, Tahrima^1,2 (AUTHOR); Crane, Harry^1,2 (AUTHOR); Symonds, Allison³ (AUTHOR)

Source: Alimentary Pharmacology & Therapeutics. Aug2022, Vol. 56 Issue 3, p510-518. 9p. 5 Charts, 3 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.

Authors : Verburgh, Myrthe L^1,2,3 (AUTHOR) ; Wit, Ferdinand W N M^1,2,4 (AUTHOR); Boyd, Anders^4,5 (AUTHOR)

Source: Open Forum Infectious Diseases. Jul2022, Vol. 9 Issue 7, p1-11. 11p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.

Authors : Jung, Chan‐Young¹ (AUTHOR); Kim, Hyung Woo¹ (AUTHOR); Ahn, Sang Hoon^1,2,3 (AUTHOR)

Source: Liver International. May2022, Vol. 42 Issue 5, p1017-1026. 10p. 1 Diagram, 4 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Fabrication of PEGylated Chitosan Nanoparticles Containing Tenofovir Alafenamide: Synthesis and Characterization.

Evaluation Effect of Tenofovir Alafenamide (TAF) in Long-Term Therapy for Chronic Hepatitis B: A Systematic Review.

Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.

Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B.

HERACLIS‐TAF: a multi‐centre prospective cohort study on 2‐year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.

Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.

One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.

Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.

اتصل بنا

اتبع